Annual Short Term Debt
$150.10 K
+$4300.00+2.95%
31 December 2023
Summary:
Inhibikase Therapeutics annual short term debt is currently $150.10 thousand, with the most recent change of +$4300.00 (+2.95%) on 31 December 2023. During the last 3 years, it has risen by +$107.60 thousand (+253.18%). IKT annual short term debt is now -39.69% below its all-time high of $248.90 thousand, reached on 31 December 2021.IKT Short Term Debt Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Short Term Debt
$145.20 K
-$7000.00-4.60%
30 September 2024
Summary:
Inhibikase Therapeutics quarterly short term debt is currently $145.20 thousand, with the most recent change of -$7000.00 (-4.60%) on 30 September 2024. Over the past year, it has dropped by -$3800.00 (-2.55%). IKT quarterly short term debt is now -85.40% below its all-time high of $994.80 thousand, reached on 31 March 2021.IKT Quarterly Short Term Debt Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IKT Short Term Debt Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +3.0% | -2.5% |
| 3 y3 years | +253.2% | -41.7% |
| 5 y5 years | -35.8% | - |
IKT Short Term Debt High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -39.7% | +253.2% | -41.7% | +2.3% |
| 5 y | 5 years | -39.7% | +253.2% | -85.4% | +241.7% |
| alltime | all time | -39.7% | +253.2% | -85.4% | +241.7% |
Inhibikase Therapeutics Short Term Debt History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $145.20 K(-4.6%) |
| June 2024 | - | $152.20 K(+0.7%) |
| Mar 2024 | - | $151.20 K(+0.7%) |
| Dec 2023 | $150.10 K(+2.9%) | $150.10 K(+0.7%) |
| Sept 2023 | - | $149.00 K(+0.7%) |
| June 2023 | - | $148.00 K(+0.7%) |
| Mar 2023 | - | $146.90 K(+0.8%) |
| Dec 2022 | $145.80 K(-41.4%) | $145.80 K(+2.7%) |
| Sept 2022 | - | $142.00 K(-42.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2021 | $248.90 K(+485.6%) | $248.90 K(0.0%) |
| Sept 2021 | - | $248.90 K(-75.0%) |
| Mar 2021 | - | $994.80 K(+2240.7%) |
| Dec 2020 | $42.50 K(-56.8%) | $42.50 K(0.0%) |
| Sept 2020 | - | $42.50 K(0.0%) |
| June 2020 | - | $42.50 K(-87.6%) |
| Mar 2020 | - | $343.70 K(+249.3%) |
| Dec 2019 | $98.40 K(-57.9%) | $98.40 K |
| Dec 2018 | $233.70 K | - |
FAQ
- What is Inhibikase Therapeutics annual short term debt?
- What is the all time high annual short term debt for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics annual short term debt year-on-year change?
- What is Inhibikase Therapeutics quarterly short term debt?
- What is the all time high quarterly short term debt for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics quarterly short term debt year-on-year change?
What is Inhibikase Therapeutics annual short term debt?
The current annual short term debt of IKT is $150.10 K
What is the all time high annual short term debt for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high annual short term debt is $248.90 K
What is Inhibikase Therapeutics annual short term debt year-on-year change?
Over the past year, IKT annual short term debt has changed by +$4300.00 (+2.95%)
What is Inhibikase Therapeutics quarterly short term debt?
The current quarterly short term debt of IKT is $145.20 K
What is the all time high quarterly short term debt for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high quarterly short term debt is $994.80 K
What is Inhibikase Therapeutics quarterly short term debt year-on-year change?
Over the past year, IKT quarterly short term debt has changed by -$3800.00 (-2.55%)